ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR131

Comprehensive Renoprotective Mechanisms of Ipragliflozin against Diabetic Nephropathy

Session Information

Category: Diabetes

  • 501 Diabetes Mellitus and Obesity: Basic - Experimental


  • Kamezaki, Michitsugu, Kyoto Chubu Medical Center, Nantan, Japan
  • Kusaba, Tetsuro, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Yamashita, Noriyuki, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Uehara, Masahiro, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Tamagaki, Keiichi, Kyoto Prefectural University of Medicine, Kyoto, Japan

Clinical and experimental investigations showed that sodium glucose co-transporter 2 inhibitors (SGLT2i) potentiate glucose-lowering and natriuretic effects and contribute to the prevention of diabetic kidney disease progression. Amelioration of glomerular hyperfiltration is one of the candidate, but the other molecular mechanisms are not fully understood.


To distinguish these different pharmacological effects on the molecular mechanisms underlying the development of diabetic kidney disease, we administered different doses of SGLT2i, ipragliflozin, (low dose: Ipra-LD, high dose: ipra-HD or vehicle) into type 2 diabetic, db/db mice for 8weeks through oral gavage.


Though body fluid volume was depleted in both Ipra-LD and Ipra-HD, only high dose Ipra significantly lowered blood glucose and reduced urinary albumin excretion. 3-nitrotyrosine (3-NT) immunostaining demonstrated that oxidative stress in the kidney was ameliorated by Ipra at dose-dependent manner. qPCR showed that expressions of tubular injury marker and NADPH oxidase 4 (Nox4) was improved in both Ipra-LD and Ipra-HD. Electron microscopy showed that Ipra improved the diabetes induced-abnormal mitochondrial cristae formation. Regarding kidney hypoxia, pimonidazole immunostaining showed that both high and low dose Ipra ameliorated the tubular hypoxia in the renal cortex where SGLT2i act. Regarding glomerulus, increased glomerular area in diabetic kidney reflecting hyperfiltration was ameliorated by both Ipra-LD and -HD. 3-NT immunostaining in glomerulus demonstrated the dose-dependent amelioration of oxidative stress in podocyte by Ipra. We further assessed the molecular mechanisms by using a glomeruli isolation technique, and found that high dose ipra preserved podocyte markers and reduced Nox4 expressions.


We verified the dose-dependent difference in the effect of ipra on diabetic nephropathy in vivo. Especially even low dose ipra improved the renal cortical hypoxia and abnormal hemodynamics in early diabetic nephropathy. In addition to these effects, high dose ipra exhibited renoprotective effects through the reduction of oxidative stress in both tubular epithelia and glomerular podocytes.